The NHS confirms that taking up to 2mg (2000 micrograms) daily is unlikely to cause harm, with no established upper limit in the UK
In cases of uncertainty with respect to how data should be interpreted, there was a group discussion regarding the paper to ensure consensus
Below, we outline some of the most notable preclinical and clinical studies related to AOD-9604's effects: In a 12-week clinical trial, participants administered 1mg/daily AOD-9604 experienced an average weight loss of 5.72lb, while the placebo group shed only 1.76lb
They're less susceptible to degradation from environmental factors once packaged
For people who cannot tolerate semaglutide's gastrointestinal burden, or who want to add a lipolysis-targeted compound to an existing protocol, the case for AOD-9604 is worth understanding honestly
Topics in Organometallic Chemistry